Evidence map›Paper›PMID 40091457›Full record

ReviewACR open rheumatology2025

Applications of Artificial Intelligence in Vasculitides: A Systematic Review.

Mahmud Omar, Reem Agbareia, Mohammad E Naffaa, Abdulla Watad, Benjamin S Glicksberg, Girish N Nadkarni, Eyal Klang

Abstract readReview
In one paragraph

Review in ACR open rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mahmud OmarIcahn School of Medicine at Mount Sinai, New York, New York, and Maccabi Healthcare Services, Tel Aviv, Israel.ORCID https://orcid.org/0009-0001-0438-0827
Reem AgbareiaOphthalmology Department, Hadassah Medical Center, Jerusalem, Israel.
Mohammad E NaffaaGalilee Medical Center, Naharyia, Israel.ORCID https://orcid.org/0000-0001-9777-2864
Abdulla WatadSheba Medical Center, Ramat-Gan, Israel.
Benjamin S GlicksbergIcahn School of Medicine at Mount Sinai, New York, New York.
Girish N NadkarniIcahn School of Medicine at Mount Sinai, New York, New York.
Eyal KlangIcahn School of Medicine at Mount Sinai, New York, New York.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveVasculitides are rare inflammatory disorders that sometimes can be difficult to diagnose due to their diverse presentations. This review examines the use of artificial intelligence (AI) to improve diagnosis and outcome prediction in vasculitis.

methodsA systematic search of PubMed, Embase, Web of Science, Institute of Electrical and Electronics Engineers Xplore, and Scopus identified relevant studies from 2000 to 2024. AI applications were categorized by data type (clinical, imaging, textual) and by task (diagnosis or prediction). Studies were assessed for risk of bias using the Prediction Model Risk of Bias Assessment Tool and Quality Assessment of Diagnostic Accuracy Studies-2.

resultsA total of 46 studies were included. AI models achieved high diagnostic performance in Kawasaki disease, with sensitivities up to 92.5% and specificities up to 97.3%. Predictive models for complications, such as intravenous Ig resistance in Kawasaki disease, showed areas under the curves between 0.716 and 0.834. Other vasculitis types, especially those using imaging data, were less studied and often limited by small datasets.

conclusionThe current literature shows that AI algorithms can enhance vasculitis diagnosis and prediction, with deep- and machine-learning models showing promise in Kawasaki disease. However, broader datasets, more external validation, and the integration of newer models like large language models are needed to advance their clinical applicability across different vasculitis types.

Identifiers

PMID40091457
PMCPMC11911543

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.